FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 STERIS plc (Exact name of registrant as specified in its charter) Ireland 98-1455064 (State or other jurisdiction of incorporation or organization) 70 Sir John Rogerson's Quay, Dublin 2, Ireland D02 R296 (Address of principal executive offices) (Zip code) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ ...

Not unlike how the market will often pay up for growth, investors will also pay up for reliability, and with a large network of hard-to-replicate outsourced sterilization facilities and a well-established in-hospital business, STERIS plc ( STE ) has benefited fromAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. ...

Key Takeaways STE posted Q3 adjusted EPS of $2.53, matching estimates, while revenues rose 9.5% yoy to $1.50 billion. STE saw sales growth across Healthcare, AST and Life Sciences, but gross margin fell 72 bps on higher costs. STE maintained fiscal 2026 guidance, expecting 8-9% revenue growth and adjusted EPS of $10.15-$10.30. STERIS plc (STE) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.53, up 9% from the year-ago quarter’s figure. The figure matched the Zacks Consensus Estima ...

STERIS (NYSE:STE) Q3 2026 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsDaniel Carestio - President and CEOJulie Winter - Head of Investor RelationsKaren Burton - CFOPatrick Wood - Managing DirectorConference Call ParticipantsBrett Fishbin - VP and Senior Equity Research AnalystJason Bednar - Research AnalystMason Etoch - Equity Research AnalystMichael Polark - Senior Equity Research Analyst in Medical DevicesMike Matson - Senior Equity Research AnalystDaniel CarestioGood day, and welcome ...

STERIS (NYSE:STE) Q3 2026 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsDaniel Carestio - President and CEOJulie Winter - Head of Investor RelationsKaren Burton - CFOPatrick Wood - Managing DirectorConference Call ParticipantsBrett Fishbin - VP and Senior Equity Research AnalystJason Bednar - Research AnalystMason Etoch - Equity Research AnalystMichael Polark - Senior Equity Research Analyst in Medical DevicesMike Matson - Senior Equity Research AnalystDaniel CarestioGood day, and welcome ...

STERIS (NYSE:STE) Q3 2026 Earnings call February 05, 2026 09:00 AM ET Speaker1Good day, and welcome to the STERIS plc third quarter 2026 conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touch-tone phone. To withdraw your question, please press star, then two. ...

Steris (STE) came out with quarterly earnings of $2.53 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $2.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.10%. A quarter ago, it was expected that this medical products maker would post earnings of $2.38 per share when it actually produced earnings of $2.47, delivering a surprise of +3.78%.Over the last four quarters, the company has surp ...

Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2026 Third Quarter DUBLIN, IRELAND - (February 4, 2026) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the thir ...

Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $ ...

Key Takeaways STE is set to report Q3 on Feb. 4, with revenues seen at $1.48B and EPS at $2.53, up year over year. STERIS expects Healthcare momentum, with capital equipment orders robust and segment revenues up 8.1%. STE's AST and Life Sciences are seen growing about 8%, aided by organic growth and MedTech demand. STERIS plc (STE) is scheduled to release third-quarter fiscal 2026 results on Feb. 4, after market close.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.4 ...